Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: Proof of concept and first application in a large population

Journal of Hepatology

Volumn 57, Issue 3, 2012, Pages 541-548

  Poynard, Thierry ^a   Munteanu, Mona ^b   Deckmyn, Olivier ^b   Ngo, Yen ^b   Drane, Fabienne ^b   Castille, Jean Marie ^b   Housset, Chantal ^a,c   Ratziu, Vlad ^a   Imbert Bismut, Franoise ^a  

^a SORBONNE UNIVERSITÉ   (France)

^b Biopredictive   (France)

^c INSERM   (France)

Author keywords

Biopsy; Fibrosis progression rates; FibroSure; FibroTest; HIV coinfection; Normal transaminases; Risk factors of fibrosis

Indexed keywords

ADEFOVIR; BIOLOGICAL MARKER; LAMIVUDINE;

ADULT; AGED; ALCOHOLIC FATTY LIVER; ARTICLE; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; EASTERN EUROPE; FEMALE; FIBROTEST; HAZARD RATIO; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MIDDLE EAST; MULTICENTER STUDY; NON INVASIVE PROCEDURE; NONALCOHOLIC FATTY LIVER; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; VALIDATION STUDY;

ADULT; AGE FACTORS; ALPHA-MACROGLOBULINS; APOLIPOPROTEIN A-I; BILIRUBIN; BIOLOGICAL MARKERS; BIOPSY; DISEASE PROGRESSION; EUROPE, EASTERN; FATTY LIVER, ALCOHOLIC; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HAPTOGLOBINS; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MIDDLE EAST;

EID: 84865134394     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2012.04.025     Document Type: Article

References (42)

1. J.F. Perz, G.L. Armstrong, L.A. Farrington, Y.J. Hutin, and B.P. Bell The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide J Hepatol 45 2006 529 538 (Pubitemid 44307383)
2. Z.M. Younossi, M. Stepanova, M. Afendy, Y. Fang, Y. Younossi, and H. Mir Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008 Clin Gastroenterol Hepatol 9 2011 524 530
3. T. Poynard, P. Bedossa, and P. Opolon For the OBSVIRC, METAVIR, CLINIVIR and DOSVIRC groups. Natural history of liver fibrosis progression in patients with chronic hepatitis C Lancet 349 1997 825 832 (Pubitemid 27129209)
4. S. Deuffic, L. Buffat, T. Poynard, and A.J. Valleron Modeling the hepatitis C epidemic in France Hepatology 29 1999 1591 1601
5. T. Poynard, V. Ratziu, F. Charlotte, Z. Goodman, J. McHutchison, and J. Albrecht Rates and risk factors of liver fibrosis progression in persons with chronic hepatitis C J Hepatol 34 2001 730 739 (Pubitemid 32488789)
6. H.H. Thein, Q. Yi, G.J. Dore, and M.D. Krahn Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression Hepatology 48 2008 418 431
7. G.L. Davis, M.J. Alter, H. El-Serag, T. Poynard, and L.W. Jennings Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression Gastroenterology 138 2010 513 521
8. T. Poynard, P. Mathurin, C.L. Lai, D. Guyader, R. Poupon, and H. Tainturier A comparison of fibrosis progression in chronic liver diseases J Hepatol 38 2003 257 265 (Pubitemid 36286537)
9. L. Castera, and M. Pinzani Non-invasive assessment of liver fibrosis: are we ready? Lancet 5 2010 1419 1420
10. P. Halfon, M. Munteanu, and T. Poynard FibroTest-ActiTest as a non-invasive marker of liver fibrosis Gastroenterol Clin Biol 32 2008 22 39
11. T. Poynard, Y. Ngo, M. Munteanu, D. Thabut, and V. Ratziu Noninvasive markers of hepatic fibrosis in chronic hepatitis B Curr Hepatitis Rep 10 2011 87 97
12. T. Poynard, Y. Ngo, H. Perazzo, M. Munteanu, P. Lebray, and J. Moussalli Prognostic value of liver fibrosis biomarkers Gastroenterol Hepatol 7 2011 445 454
13. G. Lassailly, R. Caiazzo, A. Hollebecque, D. Buob, E. Leteurtre, and L. Arnalsteen Validation of non-invasive biomarkers (FibroTest, SteatoTest and NashTest) for prediction of liver injury in patients with morbid obesity Eur J Gastroenterol Hepatol 23 2011 499 506
14. J. Vergniol, J. Foucher, E. Terrebonne, P.H. Bernard, B. Le Bail, and W. Merrouche Non-invasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C Gastroenterology 140 2011 1970 1979
15. T. Poynard, Y. Ngo, P. Marcellin, S. Hadziyannis, V. Ratziu, and Y. Benhamou Impact of adefovir dipivoxil on liver fibrosis and activity assessed with biochemical markers (FibroTest-ActiTest) in patients infected by Hepatitis B Virus J Viral Hepat 16 2009 203 213
16. T. Poynard, F. Zoulim, V. Ratziu, F. Degos, F. Imbert-Bismut, and P. Deny Longitudinal assessment of histology surrogate markers (Fibrotest-Actitest) during lamivudine therapy in patients with chronic hepatitis B infection Am J Gastroenterol 100 2005 1970 1980
17. T. Poynard, G. Lassailly, E. Diaz, K. Clement, R. Caiazzo, and J. Tordjman Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data PlosOne 7 2012 e30325
18. S. Naveau, G. Gaudé, A. Asnacios, H. Agostini, A. Abella, and N. Barri-Ova Diagnostic and prognostic values of non-invasive biomarkers of fibrosis in patients with alcoholic liver disease Hepatology 49 2009 97 105
19. T. Poynard, J. McHutchison, M. Manns, R.P. Myers, and J. Albrecht Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin Hepatology 38 2003 481 492 (Pubitemid 36919870)
20. T. Poynard, P. Lebray, P. Ingiliz, A. Varaud, B. Varsat, and Y. Ngo Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest) BMC Gastroenterol 10 2010 40
21. T. Poynard, M. Munteanu, O. Deckmyn, Y. Ngo, F. Drane, and D. Messous Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age BMC Gastroenterol 11 2011 39
22. Hintze JL. NCSS 2007 User Guide. Number Cruncher Statistical Systems software.Kaysville, Utah: NCSS; 2007.
23. R Development Core Team R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2009. Available at: http://www.R-project.org.
24. L.A. Adams, J. George, E. Bugianesi, E. Rossi, W.B. De Boer, and D. van der Poorten Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease J Gastroenterol Hepatol 26 2011 1536 1543
25. T. Poynard, M. Munteanu, F. Imbert-Bismut, F. Charlotte, D. Thabut, and S. Le Calvez Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C Clin Chem 50 2004 1344 1355 (Pubitemid 38970641)
26. P. Halfon, M. Bourliere, R. Deydier, I. Portal, R. Renou, and J. Bertrand Independent prospective multicenter validation of biochemical markers (Fibrotest-Actitest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C Am J Gastroenterol 101 2006 547 555 (Pubitemid 43340931)
27. T. Poynard, P. Ingiliz, L. Elkrief, M. Munteanu, P. Lebray, and R. Morra Concordance in a world without a gold standard: A new non-invasive methodology for improving accuracy of fibrosis markers PlosOne 3 2008 e 3857
28. T. Poynard, V. De Ledinghen, J.P. Zarski, C. Stanciu, M. Munteanu, and J. Vergniol Relative performances of FibroTest, Fibroscan and biopsy for assessing the stage of liver fibrosis in patients with chronic hepatitis C: a step toward the truth in the absence of a gold standard J Hepatol 56 2012 541 548
29. H. Fontaine, K. Petitprez, F. Roudot-Thoraval, and J.C. Trinchet Guidelines for the diagnosis of uncomplicated cirrhosis Gastroenterol Clin Biol 31 2007 504 509 (Pubitemid 46877550)
30. European Association for the Study of the Liver EASL Clinical Practice Guidelines: management of hepatitis C virus infection J Hepatol 55 2011 245 264
31. V. Ratziu, P. Giral, M. Munteanu, D. Messous, A. Mercadier, and M. Bernard Screening for liver disease using non-invasive biomarkers (FibroTest-SteatoTest-NashTest-FibroSURE) in patients with hyperlipidaemia Aliment Pharmacol Ther 25 2007 207 218 (Pubitemid 46046377)
32. S. Jacqueminet, P. Lebray, R. Morra, M. Munteanu, L. Devers, and D. Messous Screening for liver fibrosis by using a noninvasive biomarker in patients with diabetes Clin Gastroenterol Hepatol 6 2008 828 831
33. Y. Maor, D. Bashari, G. Kenet, A. Lubetsky, J. Luboshitz, and J.M. Schapiro Non-invasive biomarkers of liver fibrosis in haemophilia patients with hepatitis C: can you avoid liver biopsy? Haemophilia 12 2006 372 379
34. Y. Maor, P. Cals, D. Bashari, G. Kenet, A. Lubetsky, and J. Luboshitz Improving estimation of liver fibrosis using combination and newer non-invasive biomarker scoring systems in hepatitis C-infected haemophilia patients Haemophilia 13 2007 722 729 (Pubitemid 350018262)
35. A. Rubio, F. Monpoux, E. Huguon, R. Truchi, V. Triolo, and M.A. Rosenthal-Allieri Noninvasive procedures to evaluate liver involvement in HIV-1 vertically infected children J Pediatr Gastroenterol Nutr 49 2009 599 606
36. J. Brühl, M. Schirren, C. Wei, C. Antoni, and U. Böcker Prospective noninvasive analysis of hepatic fibrosis in patients with Crohn's disease: correlation of transient elastography and laboratory-based markers Eur J Gastroenterol Hepatol 23 2011 923 930
37. I. Goldiner, L. Blendis, Z. Halpern, and R. Oren Role of leisure-time physical activity in nonalcoholic fatty liver disease: a population-based study Hepatology 48 2008 1791 1798
38. H. Montaudié, E. Sbidian, C. Paul, A. Maza, A. Gallini, and S. Aractingi Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity J Eur Acad Dermatol Venereol 25 Suppl. 2 2011 12 18
39. J.M. Petit, B. Guiu, D. Masson, L. Duvillard, V. Jooste, and P. Buffier PNPLA3 polymorphism influences liver fibrosis in unselected patients with type 2 diabetes Liver Int 31 2011 1332 1336
40. D.L. White, S. Tavakoli-Tabasi, J. Kuzniarek, R. Pascua, D.J. Ramsey, and H.B. El-Serag Higher serum testosterone is associated with increased risk of advanced hepatitis C-related liver disease in males Hepatology 55 2012 759 768
41. V. Di Martino, P. Lebray, R.P. Myers, E. Pannier, V. Paradis, and F. Charlotte Progression of liver fibrosis in women infected with hepatitis C: long-term benefit of estrogen exposure Hepatology 40 2004 1426 1433 (Pubitemid 39657018)
42. T. Okanoue, A. Makiyama, M. Nakayama, Y. Sumida, H. Mitsuyoshi, and T. Nakajima A follow-up study to determine the value of liver biopsy and need for antiviral therapy for hepatitis C virus carriers with persistently normal serum aminotransferase J Hepatol 43 2005 599 605 (Pubitemid 41253226)